Stocks Health care FBIO

NASDAQ · Health care

Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc. brought in $68.5M of revenue over the twelve months to June 30, 2026, up 15.5% from a year earlier. Net income was $111.8M, a net margin of 163.3%. At June 30, 2026 it held $196.6M in cash against $35M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch FBIO in 60 seconds

What Fortress Biotech, Inc. does

Fortress Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBIO.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where FBIO ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $664K in cash dividends, 10% of its net income.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Fortress Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 1, 2026
   Passive stake (5% or more) SCHEDULE 13G
2. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue rose 14% to $18.7M versus the same quarter last year; diluted EPS -$0.08 versus $0.45.
3. August 13, 2026
   Quarterly results 8-K
4. June 23, 2026
   Shareholder vote results 8-K
5. May 15, 2026
   Passive stake changed SCHEDULE 13G/A
6. May 14, 2026
   Quarterly report 10-Q · period to March 31, 2026Revenue rose 22% to $16M versus the same quarter last year; diluted EPS $2.82 versus -$0.48.
7. May 14, 2026
   Quarterly results 8-K
8. April 28, 2026
   Additional proxy material DEFA14A
9. April 28, 2026
   Proxy statement DEF 14A
10. March 31, 2026
    Annual report 10-K · period to December 31, 2025Revenue rose 9.7% to $63.3M versus the prior year; diluted EPS -$0.07 versus -$2.69.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 24, 2026. Insider transactions on SEC

Insider trades

What the people running Fortress Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns FBIO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 55 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

8 insiders reported holding 9,200,936 shares in total, about $20M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about FBIO

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBIO.

Is Fortress Biotech, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $111.8M on revenue of $68.5M, a net margin of 163.3%.

How much revenue does Fortress Biotech, Inc. make?

Over the twelve months to June 30, 2026 Fortress Biotech, Inc. reported revenue of $68.5M. That is 15.5% more than a year earlier.

When did Fortress Biotech, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 1, 2026.

Similar companies

Compare FBIO with

Compare FBIO with any company

Follow FBIO

Get an email when Fortress Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow FBIO: get an email when it files

Where the numbers come from

Financial figures are the values Fortress Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.